Expanding the genetic spectrum of inherited peripheral neuropathies in complex neurogenetic disorders using whole-exome sequencing.
11 affiliations
- 1Department of Medical Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran.
- 2Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
- 3Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran.
- 4Rare Pediatric Neurological Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- 5Department of Medical Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran. [email protected].
- 6Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK. [email protected].
- 7Institute for Auditory Neuroscience and Inner Ear Lab, University Medical Center Göttingen, Göttingen, Germany. [email protected].
- 8Auditory Neuroscience and Optogenetics Laboratory, German Primate Center, Göttingen, Germany. [email protected].
- 9Collaborative Research Center 1690 (CRC 1690), University of Göttingen, Göttingen, Germany. [email protected].
- 10Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. [email protected].
- 11Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. [email protected].
Abstract
Inherited peripheral neuropathies (IPNs) represent a clinically and genetically heterogeneous group of disorders affecting sensory, motor, autonomic functions, and can also present as a part of complex neurogenetic syndromes. Charcot-Marie-Tooth disease (CMT) is the most prevalent type of IPN. Despite advances in genetic testing, the diagnostic process remains challenging due to genetic heterogeneity and overlapping clinical phenotypes. We performed a comprehensive genetic evaluation of 126 patients presenting with symptoms of IPN. Nineteen patients with a typical CMT phenotype were initially screened for PMP22 copy number variations using Multiplex Ligation-dependent Probe Amplification (MLPA). Whole-exome sequencing (WES) was subsequently performed in 107 patients. Of these, 72 (63.7%) were classified as pathogenic or likely pathogenic, including 36 novel variants (50.0%), yielding an overall WES diagnostic rate of 62.6% (67/107). CMT-spectrum disorders identified by MLPA (n = 19 patients) and WES (n = 33 patients) accounted for 41.3% (52/126) of the study cohort. Additional diagnoses included hereditary sensory neuropathy 3.97% (5/126), distal hereditary motor neuropathy 4.76% (6/126), spastic paraplegia 3.97% (5/126), spinocerebellar ataxia 5.56% (7/126), spastic ataxia 8.73% (11/126), mitochondrial disease 7.94% (10/126), and other complex neurogenetic disorders 23.81% (30/126). Our findings highlight the utility of genomic sequencing approaches for resolving clinically heterogeneous neuropathy presentations and demonstrate the value of WES in a highly consanguineous Iranian cohort. These results support the role of WES in advancing precision medicine approaches for inherited neuropathies.
Related
- Single-cell RNA sequencing delineates compositional and transcriptional changes of porcine peripheral blood mononuclear cell populations following Salmonella I 4,[5],12:i:- inoculation
- Single-cell transcriptome sequencing analysis of peripheral blood mononuclear cells reveals immune signatures in patients with polymyalgia rheumatica
- Behavioural and neurogenetic evidence for emotion primitives in the fruit fly Drosophila from an open field test
- Atypical Presentation of Hereditary Sensory and Autonomic Neuropathy Type IIB: A Family of HSAN IIB With Spasticity Presentation and Review on Sensory Neuropathies With Spasticity
- A genetic profile of hereditary neuropathies in two Southern African cohorts
BibTeX
@article{torbati2026expanding,
title = {{Expanding the genetic spectrum of inherited peripheral neuropathies in complex neurogenetic disorders using whole-exome sequencing.}},
author = {Paria Najarzadeh Torbati and Reza Boostani and Mojtaba Safi and Najmeh Ahangari and Mohammad Doosti and Hasan Badpar and Mehran Beiraghi Toosi and Ehsan Ghayoor Karimiani and Barbara Vona},
journal = {Neurogenetics},
year = {2026},
month = oct,
doi = {10.1007/s10048-026-00952-w},
url = {https://europepmc.org/article/MED/42955121},
note = {CC BY},
}
RIS
TY - JOUR
TI - Expanding the genetic spectrum of inherited peripheral neuropathies in complex neurogenetic disorders using whole-exome sequencing.
AU - Paria Najarzadeh Torbati
AU - Reza Boostani
AU - Mojtaba Safi
AU - Najmeh Ahangari
AU - Mohammad Doosti
AU - Hasan Badpar
AU - Mehran Beiraghi Toosi
AU - Ehsan Ghayoor Karimiani
AU - Barbara Vona
PY - 2026
DA - 2026/10/29
JO - Neurogenetics
DO - 10.1007/s10048-026-00952-w
UR - https://europepmc.org/article/MED/42955121
AB - Inherited peripheral neuropathies (IPNs) represent a clinically and genetically heterogeneous group of disorders affecting sensory, motor, autonomic functions, and can also present as a part of complex neurogenetic syndromes. Charcot-Marie-Tooth disease (CMT) is the most prevalent type of IPN. Despite advances in genetic testing, the diagnostic process remains challenging due to genetic heterogeneity and overlapping clinical phenotypes. We performed a comprehensive genetic evaluation of 126 patients presenting with symptoms of IPN. Nineteen patients with a typical CMT phenotype were initially screened for PMP22 copy number variations using Multiplex Ligation-dependent Probe Amplification (MLPA). Whole-exome sequencing (WES) was subsequently performed in 107 patients. Of these, 72 (63.7%) were classified as pathogenic or likely pathogenic, including 36 novel variants (50.0%), yielding an overall WES diagnostic rate of 62.6% (67/107). CMT-spectrum disorders identified by MLPA (n = 19 patients) and WES (n = 33 patients) accounted for 41.3% (52/126) of the study cohort. Additional diagnoses included hereditary sensory neuropathy 3.97% (5/126), distal hereditary motor neuropathy 4.76% (6/126), spastic paraplegia 3.97% (5/126), spinocerebellar ataxia 5.56% (7/126), spastic ataxia 8.73% (11/126), mitochondrial disease 7.94% (10/126), and other complex neurogenetic disorders 23.81% (30/126). Our findings highlight the utility of genomic sequencing approaches for resolving clinically heterogeneous neuropathy presentations and demonstrate the value of WES in a highly consanguineous Iranian cohort. These results support the role of WES in advancing precision medicine approaches for inherited neuropathies.
SN - 1364-6745
SN - 1364-6753
ER -